Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Earnings for Summit Therapeutics Inc. (SMMT)
Earnings in 2023 (TTM): $-615,874,000
According to Summit Therapeutics Inc.'s latest financial reports the company's current earnings (TTM) are $-615,874,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Summit Therapeutics Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-615,874,000 | $-614,928,000 |
| 2022 | $-78,782,000 | $-74,381,000 |
| 2021 | $-88,602,000 | $-86,147,000 |
| 2020 | $-52,910,000 | $-52,697,000 |
| 2019 | $-36,469,928 | $-30,662,295 |
| 2018 | $6.6 M | $9.87 M |
| 2017 | $-15,418,696 | $-10,093,704 |
| 2016 | $-32,132,545 | $-26,712,748 |
| 2015 | $-28,691,875 | $-24,336,680 |
| 2014 | $-19,074,883 | $-17,120,687 |
| 2013 | $-11,051,729 | $-10,050,475 |
| 2012 | $-7,212,017 | $-6,673,406 |
| 2011 | $-4,707,767 | $-4,230,395 |
| 2010 | $-9,362,093 | $-7,421,943 |
| 2009 | $-9,296,418 | $-8,657,379 |
| 2008 | $-18,880,978 | $-32,289,355 |
| 2007 | $-21,939,191 | $-20,127,662 |
| 2006 | $-6,882,956 | $-5,923,776 |
| 2005 | $-2,171,763 | $-1,893,286 |
| 2004 | $-131,799 | $-86,611 |
| 2003 | $-41,963 | $-41,963 |